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Background and aims: We recently showed that plasma cholesteryl ester transfer protein (CETP) is
mainly derived from VSIG4-positive Kupffer cells. Activation of these cells by the bacterial endotoxin
lipopolysaccharide (LPS) strongly decreases CETP expression. As Kupffer cell activation plays a detri-
mental role in the progression of non-alcoholic fatty liver disease (NAFLD), we aimed to study if
metabolic liver inflammation is also associated with a decrease in hepatic and circulating CETP.
Methods: We collected plasma and liver biopsy samples at various stages of NAFLD from 93 obese in-
dividuals who underwent bariatric surgery. Liver lobular inflammation was histologically determined,
and liver CETP expression, CETP positive cells, circulating CETP concentrations, and liver VSIG4 expression
were quantified.
Results: Mean (SD) plasma CETP concentration was 2.68 (0.89) mg/mL. In the presence of liver inflam-
mation, compared to the absence of pathology, the difference in hepatic CETP expression was 0.03
arbitrary units (95% CI -0.26, 0.20), the difference in number of hepatic CETP positive cells (range 11e140
per mm2) was 20.0 per mm2 (95% CI -41.6, 1.9), and the difference in plasma CETP was 0.35 mg/mL
(95% CI -0.80, 0.10). Hepatic VSIG4 expression was not associated with liver inflammation (0.00; 95% CI
-0.15, 0.15).
Conclusions: We found no strong evidence for a strong negative association between metabolic liver
inflammation and CETP-related outcomes in obese individuals, although we observed consistent trends.
These data indicate that metabolic liver inflammation does not mimic the strong effects of LPS on the
hepatic expression and production of CETP by Kupffer cells.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cholesteryl ester transfer protein (CETP) facilitates the transfer
of cholesteryl esters from high-density lipoproteins (HDL) towards
(very) low-density lipoproteins ((V)LDL), coupled to a net flux of
triglycerides from (V)LDL to HDL, thereby contributing to an
atherogenic lipoprotein profile [1]. Recently, we showed in human
studies that circulating levels of CETP are mainly determined byCenter, Dept. Medicine, Div.
C, Leiden, The Netherlands.
B.V. This is an open access article uresident hepatic macrophages (Kupffer cells) [2], without a
contribution of adipose tissue [3]. In fact, hepatic Kupffer cell
content strongly correlated with both hepatic CETP expression and
plasma CETP concentration [2].
Besides its established role in lipid metabolism, accumulating
evidence suggests that CETP is involved in immunity and inflam-
matory processes [4]. This is in line with the primary expression of
CETP by Kupffer cells, which play a pivotal role in inflammation and
host defence against e.g. Gram-negative bacterial infections.
Kupffer cells can detect lipopolysaccharide (LPS), a potent endo-
toxin released from Gram-negative bacteria, and induce an anti-
bacterial response via the release of pro-inflammatory cytokinesnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[5]. Interestingly, LPS reduces liver CETP expression and circulating
CETP concentrations in CETP-transgenic mice [6]. Similarly, LPS,
TNF-a and IL-1b decrease CETP expression and CETP concentration
in hamsters [7]. LPS administration also decreased plasma CETP
concentrations in humans [8]. Collectively, inflammatory stimuli
seem to downregulate CETP expression by Kupffer cells.
Recently, we showed in CETP-expressing mice that hepatic
expression of CETP is confined to a specific subset of Kupffer cells
that also express Vsig4, which is a marker of resting Kupffer cells
[8]. Also in humans, hepatic VSIG4 expression correlated with both
liver CETP expression and plasma CETP concentration [8]. In this
same study, we showed that LPS inoculation of mice markedly
reduced liver CETP expression and production, accompanied by a
similar loss of the Kupffer cell marker Vsig4. Combined, these data
indicate that liver CETP expression is exclusively confined to a
resting Kupffer cell subset, which loses CETP expression when
activated by LPS.
Although the mechanisms by which inflammatory stimuli
reduce CETP expression are not yet fully understood, they may
counteract liver X receptor (LXR)-induced CETP expression. LXRs
regulate a variety of genes to control cholesterol and lipid ho-
meostasis and protect cells from an overload of toxic sterol [9]. CETP
gene transcription is induced via an LXRa response element in the
CETP promoter region [10,11]. Natural ligands for LXRa are oxidized
derivatives of cholesterol (i.e. oxysterols) [12,13] and the choles-
terol precursor desmosterol [14]. Interestingly, in vitro exposure of
murine macrophages to LPS, TNF-a or interferon g (IFN-g) sup-
presses an LXRa-induced increase in CETP expression [15]. In
addition, we recently showed that LPS also reduces CETP expression
as induced by an LXR agonist in human macrophages [8]. Taken
together, LXRa-induced expression of CETP by Kupffer cells may be
counteracted by inflammatory stimuli.
Apart from their beneficial role in host defence [5], Kupffer cells
play a detrimental role in the progression of non-alcoholic fatty
liver disease (NAFLD) from simple steatosis to non-alcoholic stea-
tohepatitis (NASH), which is characterized by liver inflammation
[16e21]. With the growing prevalence of obesity worldwide, an
increasing number of individuals suffer from NAFLD [22]. The
central role of Kupffer cells in NAFLD is partly explained by excess
free cholesterol that cannot be detoxified by esterification, leading
to cholesterol crystallization not only within hepatocytes but also
within Kupffer cells, which consequently activates inflammatory
pathways [16,23,24]. The aim of the present study is to determine
whether metabolic liver inflammation, as a component of NAFLD, is
associated with a decrease in liver CETP expression and CETP pro-
duction similar to LPS. To this end, we collected liver biopsy sam-
ples at various stages of NAFLD from a bariatric surgery cohort to
histologically determine liver inflammation, and to quantify liver
CETP and VSIG4 expression, liver lipids, liver CETP positive cells and
circulating CETP concentrations.
2. Materials and methods
2.1. Study design and study population
The study population consisted of 93 severely obese men and
women who underwent elective bariatric surgery between 2006
and 2009 at the Department of General Surgery, Maastricht Uni-
versity Medical Center (Maastricht, The Netherlands) [25]. Subjects
using anti-inflammatory drugs or with acute or chronic inflam-
matory diseases, degenerative diseases, and subjects reporting
alcoholic intake >10 g/day were not included in this study. There
were no specific dietary protocols that participants had to follow
before surgery. Venous blood samples were drawn on the morningof surgery after 8 h of overnight fasting. During surgery, wedge
biopsies of the liver were taken. The study was approved by the
medical ethics board of Maastricht University Medical Center, in
line with the ethical guidelines of the 1975 Declaration of Helsinki.
Written informed consent was obtained from each participant.
2.2. Data collection
Because of the limited samples available, random samples from
this study population were selected for data collection. Liver CETP,
VSIG4 mRNA expression were determined from microarrays of 82
samples, as described previously [2,25]. Similarly, mRNA expres-
sion of the inflammatory markers tumor necrosis factor a (TNFa),
interleukin 1b (IL1b), interleukin 6 (IL6) and Toll-like receptor 4
(TLR4) was determined to assess the association with different
components of NAFLD. Biopsy specimens were formalin-fixed and
paraffin-embedded, and subsequently immunohistochemistry was
performed. The number of CETP positive cells per mm [2] was
obtained (n¼ 44) [2]. Plasma CETP concentrations were measured
for 73 participants fromwhomplasmawas availablewith ELISA kits
(DAIICHI CETP ELISA, Alpco, Salem, USA), according to the manu-
facturer's instructions. Wemeasured CETP concentration instead of
exogenous CETP activity, both of which are however highly corre-
lated [26e28].
2.3. Histology
For histological scoring of the liver biopsies, Hematoxylin-eosin
and Klatskin (Masson) trichrome stains were used to assess histo-
pathology. Samples were scored for steatosis (n¼ 93), lobular
inflammation (n¼ 89), and hepatocellular ballooning (n¼ 89), by
an experienced liver pathologist who was blinded for clinical and
biochemical parameters, according to the criteria of the NAFLD
activity score described by Kleiner et al. [29] (see Supplementary
Data).
2.4. Nuclear magnetic resonance (NMR) spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy was used to
measure total cholesterol, free cholesterol, cholesteryl ester and
triglyceride contents in 68 liver samples. A detailed description of
the method can be found in the Supplementary Data.
2.5. Biochemical analyses
Plasma concentrations of total cholesterol, LDL-cholesterol,
HDL-cholesterol, triglycerides, alanine transaminase (ALT), and
aspartate transaminase (AST) were measured, as described before
[25].
2.6. Statistical analyses
We assessed the associations of the following determinants
with CETP-related outcomes: steatosis score, lobular inflammation
score, hepatocellular ballooning score, presence of NASH, plasma
ALT concentration, plasma AST concentration, liver total cholesterol
content, liver free cholesterol content, liver cholesteryl ester con-
tent and liver triglyceride content. For steatosis, lobular inflam-
mation, hepatocellular ballooning, and NASH separately, the
presence of disease (score 1) was compared with absence of pa-
thology (score 0), as defined by the criteria of the NAFLD activity
score [29]. As CETP-related outcome variables we used liver CETP
expression, CETP protein positive cells, and plasma CETP concen-
tration. Linear regression analyses were used to determine all as-
sociations. Crude models (Model 1) were adjusted for age and sex
Table 1
Characteristics of the elective bariatric surgery cohort aged 17e67 years (n¼ 93a), stratified by sex.
Characteristic Men Women
Number of participants (% of total) 26 (28%) 67 (72%)
Age (year) 46 (11) 43 (9)
BMI (kg/m2) 50 (10) 45 (9)
Fasting plasma concentrations
CETP (mg/mL) 2.56 (0.92) 2.72 (0.88)
Total cholesterol (mmol/L) 4.66 (0.89) 5.26 (1.15)
HDL-cholesterol (mmol/L) 0.88 (0.27) 1.02 (0.40)
LDL-cholesterol (mmol/L) 2.90 (0.86) 3.34 (1.03)
Triglycerides (mmol/L) 1.95 (0.94) 2.33 (2.27)
ALT (IU/L) 26.6 (11.8) 26.5 (17.6)
AST (IU/L) 27.1 (10.4) 23.5 (13.1)
Liver biopsies
Total cholesterol content (nmol/mg protein)b 12 (9) 37 (68)
Free cholesterol content (nmol/mg protein)b 8 (6) 25 (44)
Cholesteryl ester content (nmol/mg protein)b 4 (3) 11 (26)
Triglyceride content (nmol/mg protein)b 90.4 (71.1) 268 (618)
Number of patients with NAFLD activity score 5 (% of total men or women)c 4 (15%) 12 (18%)
Results are presented as mean (SD) or percentage.
a Missing data: n¼ 1 for BMI, n¼ 20 for plasma CETP concentration, n¼ 6 for total cholesterol concentration, n¼ 7 for HDL-cholesterol, LDL-cholesterol and
triglyceride concentration, n¼ 6 for ALT and AST concentration, n¼ 4 for NAFLD activity score, n¼ 25 for liver content of total cholesterol, free cholesterol, cho-
lesteryl esters and triglycerides.
b Measured with NMR.
c A NAFLD activity score5 is indicative of NASH [29].
L.L. Blauw et al. / Atherosclerosis 275 (2018) 149e155 151(Model 2). Differences were expressed as beta coefficients with
corresponding 95% CIs. Liver sterol and triglyceride contents and
liver transaminases were non-normally distributed, and therefore
we used their natural logarithms in the analyses. For interpretation
purposes, beta coefficients were multiplied by ln(1.1), and differ-
ences with corresponding 95% CIs were expressed per 10% relative
increase in the determinant. In addition, we assessed the correla-
tions between NMR-determined liver sterol and triglyceride data
and reported Spearman's correlation coefficient. All analyses were
performed using STATA Statistical Software (Statacorp, College
Station, Texas, USA), version 12.0.
3. Results
3.1. Population characteristics
Table 1 shows the characteristics of the elective bariatric surgery
cohort. Body mass index (BMI) ranged from 30.6 to 73.6 kg/m2.
Mean age was 44 years, and most participants were women. Mean
(SD) CETP concentration was 2.68 (0.89) mg/mL in the total popu-
lation, 2.56 (0.92) mg/mL for men and 2.72 (0.88) mg/mL for women.
15% of men and 18% of women had a NAFLD activity score 5,
which is indicative of NASH [29]. Plasma ALT concentration was
comparable between men and women, and plasma AST concen-
trationwas somewhat lower inwomen. Liver sterol and triglyceride
contents were higher in women than in men.
3.2. Lobular inflammation and hepatocellular ballooning tend to
associate with less CETP positive cells in the liver and a lower
plasma CETP concentration
Associations of the separate NAFLD activity score components,
i.e. steatosis, lobular inflammation and ballooning score, with the
CETP-related outcomes are presented in Fig. 1 and Supplementary
table 2. The age and sex-adjusted difference in CETP mRNA
expression in the liver for an inflammation score1 comparedwith
a score of 0 was 0.03 arbitrary units (95% CI -0.26, 0.20). Com-
parable small, null associations were observed for steatosis and
ballooning scores. The number of CETP positive cells per mm2 liver
ranged from 11 to 140. The presence of liver lobular inflammationwas associated with a lower number of CETP positive cells of 20.0
per mm2 (95% CI -41.6, 1.9). Steatosis and ballooning scores were
also negatively associated with CETP positive cell number, although
confidence intervals overlapped with zero. Plasma CETP concen-
tration was within the range of 1.45e5.56 mg/mL. The presence of
lobular inflammation was associated with a lower plasma CETP
of 0.35 mg/mL (95% CI -0.80, 0.10), although confidence intervals
overlapped with zero. Hepatocellular ballooning was associated
with a0.42 mg/mL (95% CI -0.84,0.00) mg/mL lower plasma CETP
concentration, which represents approx. 15% of the mean CETP
concentration. Steatosis score also showed a negative association
with CETP concentration, although the confidence intervals over-
lapped with zero. Steatosis, inflammation and ballooning scores
were not negatively associated with VSIG4 expression (Fig. 1,
Supplementary table 2). Associations of the separate NAFLD activity
score components with mRNA expressions of TNFa, IL1b, IL6 and
TLR4 can be found in Supplementary figure 1 and Supplementary
table 3. In the presence of liver inflammation TNFa expression
was increased (0.17 arbitrary units; 95% CI 0.03, 0.31) and IL1b (0.35
arbitrary units; 95% CI -0.10, 0.80) and IL6 (0.26 arbitrary units; 95%
CI -0.18, 0.70) expression tended to be increased, compared to
absence of liver inflammation. For the other two stages of NAFLD,
i.e. steatosis and ballooning, no clear associations were observed
with the mRNA expression of these genes. Also, TLR4 mRNA
expression was increased in the presence of liver inflammation
(0.14 arbitrary units; 95% CI 0.02, 0.26).3.3. CETP-related outcomes are not different in patients with a
NAFLD activity score 5
A NAFLD activity score 5 was associated with a higher ALT
concentration of 18.2 IU/L (95% CI 10.1, 26.3) and a higher AST
concentration of 13.5 IU/L (95% CI 7.2, 19.8). However, no difference
in CETP-related outcomes was observed between participants with
a NAFLD activity score 5 compared with participants with a
NAFLD activity score <5 (Supplementary figure 2, Supplementary
table 4). Plasma ALT and AST concentrations were negatively
associated with liver CETP expression, although associations were
weak (Supplementary figure 3, Supplementary table 5). Age- and
sex-adjusted differences in CETP expression were 0.020 arbitrary
Fig. 1. CETP-related outcomes, but not liver VSIG4 expression, show a consistent trend for negative association with metabolic liver steatosis, inflammation and ballooning.
Age and sex-adjusted differences (i.e. beta coefficients from linear regression) in (A) liver CETPmRNA expression, (B) liver CETP positive cells, (C) plasma CETP concentration, and (D)
liver VSIG4mRNA expression between absence (score 0, reference category) and presence (score1) of liver steatosis, lobular inflammation and ballooning. Error bars represent 95%
confidence interval.
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-0.047, 0.001) per 10% relative increase in plasma ALT and AST
concentration, respectively. Associations of both liver trans-
aminases with CETP positive cells and CETP concentration were
also negative, although effect sizes were small and confidence in-
tervals overlapped with zero (Supplementary figure 3,
Supplementary table 5).
3.4. Associations of liver sterol and triglyceride contents with CETP-
related outcomes were around the null
NMR-determined liver sterol and triglyceride data clearly show
that hepatic contents of total cholesterol and free cholesterol were
highly correlated (r2¼ 0.97, P< 0.0001). In addition, the correla-
tions between the hepatic content of total cholesterol and choles-
teryl esters (r2¼ 0.77, P< 0.001), and between total cholesterol and
triglycerides (r2¼ 0.71, P< 0.001) were high. Strikingly, all of the
associations of liver triglyceride and sterol contents with CETP-
related outcomes were around the null (Fig. 2, Supplementary
table 6).
4. Discussion
VSIG4-positive Kupffer cells have recently been identified as the
main determinants of circulating CETP levels [2,8], but the influ-
ence of the hepatic environment on CETP expression and CETP
production is far from elucidated. Based on previous studies,
showing that inflammatory stimuli downregulate CETP expression
in mice and in vitro [6,7,15,30,31], we hypothesized that hepatic
CETP expression and circulating CETP concentrations are decreased
in humans with metabolic liver inflammation. Therefore, we aimed
to study the associations of histologically-determined liverinflammation, as a component of NAFLD, with liver CETP expres-
sion, CETP positive cells and circulating CETP concentrations, using
liver biopsy data from an elective bariatric surgery cohort. We
found no strong evidence for a negative association between liver
lobular inflammation and CETP-related outcomes, as 95% confi-
dence intervals overlapped with zero. However, we did observe
consistent trends towards less CETP expression, a lower number of
CETP positive cells, and a lower circulating CETP concentration
when liver inflammation was present. In line, we also observed
trends for a negative association of ALT and AST concentrations,
both markers for liver damage, with CETP-related outcomes.
It is interesting to speculate why only limited associations were
observed between metabolic inflammation and CETP-related out-
comes. Previous animal and in vitro studies showed a decrease in
CETP expression specifically in response to infection-related in-
flammatory stimuli, such as LPS, IL-1b and IFN-g [6,7,15]. In addi-
tion, we recently showed that LPS also reduces plasma CETP
concentration in humans [8]. In the present study, all participants
were morbidly obese, and individuals who used anti-inflammatory
drugs or had acute or chronic inflammatory diseases were not able
to participate. Thus, liver inflammation in the present study was
assumed to be metabolically-induced. Interestingly, metabolic liver
inflammation, which is a component of NAFLD, has been shown to
differ from infection-induced liver inflammation [32]. In mice, LPS
and IL-1b cause intrahepatic inflammation that is exclusively
mediated by macrophages, while metabolic triggers (i.e. carbohy-
drate and cholesterol) of liver inflammation induce a NASH
phenotype with mixed intrahepatic infiltrates including both
macrophages and neutrophils [32]. Since CETP is primarily pro-
duced by hepatic macrophages, infection-related inflammatory
stimuli may affect hepatic expression and production of CETP to a
different extent than metabolic triggers.
Fig. 2. Associations of liver sterol and triglyceride contents with CETP-related out-
comes are all around the null.
Age and sex-adjusted differencesa in (A) liver CETP mRNA expression, (B) liver CETP
positive cells and (C) plasma CETP concentration, per 10% relative increase in the
plasma concentrations of ALT and AST. Error bars represent 95% confidence interval. a
(Beta coefficients from linear regression)*ln(1.1), i.e. difference per 10% relative in-
crease in liver sterol and triglyceride content.
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with adverse changes in the gut microbiota [33], which may lead to
elevated penetration of LPS from the gut into the circulation, a
condition described as metabolic endotoxemia [34,35]. Indeed, in
our study we showed that hepatic TLR4 mRNA expression was
higher in the presence of liver inflammation. The TLR4 signalling
pathway can be activated by LPS to release pro-inflammatorycytokines, such as TNFa [36,37], which was also higher in our study
in the presence of liver inflammation. It has been shown that low-
dose LPS administration leads to a low-grade chronic inflammatory
state [34], which possibly downregulates CETP production to a
certain extent.
Notably, severe sepsis was previously shown in humans to
largely decrease CETP concentration, i.e. by 25% after 3 days of
sepsis [38], while we only observed a trend towards a negative
association between metabolic liver inflammation and CETP-
related outcomes. This is in line with a previous study in CETP-
transgenic mice, in which we observed that long term high-fat
diet-induced obesity did not affect plasma CETP concentration
[39]. The difference between metabolic versus infection-induced
liver inflammation is further highlighted by our observation that
VSIG4 expression, which is a marker of resting Kupffer cells, was not
lower in the presence of metabolic liver inflammation, while we
previously showed that LPS injection largely reduced both Vsig4
and CETP expression, at least in mice [8]. Taken together, we pro-
pose that acute and/or whole-body inflammatory responses to
invading pathogens are required to induce a robust reduction in
CETP production by Kupffer cells.
In the context of infection-induced versus metabolic liver
inflammation, it is important to consider the biological relevance
underlying the relationship between CETP and inflammation. CETP
mediates the bidirectional exchange of triglycerides and cholesteryl
esters between (V)LDL and HDL, thereby raising LDL-cholesterol
and decreasing HDL-cholesterol, which is generally regarded as a
biologically unwanted proatherogenic property of CETP. Since HDL
is known for its inflammation-modulatory properties and benefi-
cial role in host-defence [40e43], we reason that the biological
function of CETP in humans is modulation of the immune response
via HDL. In fact, the reduction in CETP expression by Kupffer cells in
CETP-transgenic mice as induced by LPS is accompanied by an in-
crease in HDL [8]. We thus postulate that inflammatory stimuli
activate resting Kupffer cells to decrease CETP expression and
thereby raise HDL to combat invading microorganisms. In line with
this hypothesis, it seems plausible that metabolic liver inflamma-
tion will not largely reduce the expression and production of CETP.
Comparable with liver inflammation, liver steatosis score also
tended to be negatively associated with the number of CETP posi-
tive cells. This negative effect direction can possibly be explained by
a decrease in macrophage cell number per area rather than by an
absolute decrease in Kupffer cell number, as the presence of stea-
tosis results in occupation of a larger area of the microscopic field
by lipid-filled hepatocytes. This is a plausible explanation, as as-
sociations between NMR-determined triglyceride content and
CETP-related outcomes were all around zero. NMR triglyceride
measurements were expressed per mg protein, and can therefore
be interpreted as mean triglyceride content per hepatocyte.
Therefore, in the light of the NMR findings, the negative association
between histologically-determined steatosis and CETP-related
outcomes is most likely explained by the measurement technique.
This study is one of the first studies to include NMR spectros-
copy for the quantitative analysis of several lipid and sterol classes
in human liver biopsies. By using NMR spectroscopy, we revealed a
strong correlation between hepatic contents of total cholesterol
and free cholesterol (R2¼ 0.97) as well as those of total cholesterol
and triglycerides (R2¼ 0.71). The finding that none of the measured
liver sterol components (i.e. total cholesterol, free cholesterol, nor
cholesteryl esters) was associated with CETP expression in the
present study, may seem counterintuitive given that CETP expres-
sion is under the control of LXRa [10,11]. Cholesterol derivatives
activate LXRa [12,13], which subsequently binds to an LXR-
response element in the CETP promotor region to increase gene
transcription [10,11]. It should be realized that we measured
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desmosterol. For future studies, mass spectrometric platforms
might complement NMR analysis to measure oxysterols and des-
mosterol, as the commonly observed low concentrations are likely
out of the measurement range of NMR spectroscopy.
Notably, comparedwith participants with a NAFLD activity score
<5, CETP-related outcomes were not different in participants with a
NAFLD activity score 5, which is indicative of NASH [29]. This
score is composed of three summed, separate components (i.e.
steatosis, lobular inflammation and ballooning scores) [29]. We
argue that this score may not be sufficiently specific to detect an
association of specific aspects of NAFLD with CETP-related out-
comes, which is the main reason that we studied the associations
between the different components of the NAFLD activity score and
CETP-related outcomes separately. The same reasoning may also
hold for plasma ALT and AST concentrations, which are relatively
non-specific markers for liver function [44]. Associations of both
liver transaminases with CETP-related outcomes were around the
null.
The main strength of the present study is the availability of liver
biopsies from a population of obese men and women, with a high
prevalence of metabolic liver inflammation. Liver samples were
extensively characterized with regard to CETP, sterol and triglyc-
eride content, steatosis, inflammation and cell damage. Also,
several limitations of the study design should be considered. Firstly,
inherent to the observational cross-sectional design we cannot
exclude residual confounding, or draw conclusions on causality.
Secondly, this study possibly lacked power to identify statistically
significant differences in CETP-related outcomes due to the rela-
tively small study population size. Lastly, results may not be
generalizable to other populations, as participants were selected
from an obese cohort that underwent bariatric surgery. Remark-
ably, although NAFLD is more common in men than inwomen [45],
in the present study liver sterol and triglyceride contents were
higher inwomen than in men. This may suggest that bigger hepatic
lipid droplets are present in women. However, sex differences in
disease phenotype are far from understood. Severity of steatosis
has been associated with clustering of risk factors for the metabolic
syndrome. Possibly differences in these risk factors between men
andwomenmay partly explain different liver steatosis phenotypes.
Moreover, hormonal factors have also been proposed to explain
part of the differences between men and women [45,46]. Clearly,
further research in this area is warranted.
In conclusion, we found no strong evidence for a negative as-
sociation between metabolic liver inflammation and CETP-related
outcomes, although we observed consistent trends. Given that
infection-related inflammatory stimuli do significantly decrease
CETP expression by Kupffer cells, our results suggest that metabolic
liver inflammation affects the expression and production of CETP
by Kupffer cells to a more modest extent than infection-induced
liver inflammation. It is tempting to speculate that acute and/or
whole-body inflammatory responses to invading pathogens are
required to induce a robust reduction in CETP production by
Kupffer cells. Further research into the effects of liver inflammation
and host defence on hepatic CETP production is, therefore, eagerly
awaited.
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